Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00534274
Recruitment Status : Completed
First Posted : September 24, 2007
Last Update Posted : December 16, 2014
Information provided by (Responsible Party):

Brief Summary:

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using 3'-deoxy-3'-(18F) fluorothymidine, may be effective in assessing the response to chemotherapy before surgery in treating locally advanced breast cancer.

PURPOSE: This clinical trial is studying how well positron emission tomography using 3'-deoxy-3'-(18F) fluorothymidine works in treating women with locally advanced cancer in one breast who are receiving chemotherapy.

Condition or disease Intervention/treatment Phase
Breast Cancer Other: 3'-deoxy-3'-[18F]fluorothymidine Not Applicable

Detailed Description:



  • Evaluate the efficacy of positron emission tomography (PET) utilizing 3'-deoxy-3'-(18F) fluorothymidine (^18F-FLT) to correctly identify response to neoadjuvant chemotherapy in women with locally advanced unilateral breast cancer.
  • Correlate PET-^18F-FLT results with histological response.


  • Evaluate the correlation of early changes in tumor uptake of ^18F-FLT after the first course of chemotherapy with complete response after treatment completion.
  • Evaluate the correlation of early changes in tumor uptake of ^18F-FLT with histologic response in biopsies obtained after 1 course of chemotherapy.
  • Determine if the initial intensity of tumor uptake is a predictive value of response to chemotherapy.
  • Determine if initial intensity of tumor uptake of ^18F-FLT varies according to histologic type of tumor, indices of proliferation, and tumor cellularity before therapy.
  • Determine if the tumor uptake of ^18F-FLT during therapy varies according to histologic type of tumor, indices of proliferation, and tumor cellularity before therapy.
  • Evaluate the role of TK1 on the kinetics of ^18 F-FLT.
  • Analyze serum.
  • Research biomarkers of genomics, transcription, and proteomics.
  • Evaluate the toxicity of ^18F-FLT.

OUTLINE: This is a multicenter study.

Patients receive 3'-deoxy-3'-(18F) fluorothymidine (^18F-FLT) IV and undergo positron emission tomography (PET) before the first and second courses of neoadjuvant chemotherapy. Patients receiving bisequential chemotherapy undergo ^18F-FLT-PET before the change in drugs (usually the fourth or fifth course). All patients undergo a final ^18F-FLT-PET after the last chemotherapy course but before surgery.

After completion of study therapy, patients are followed for 1 month.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Study of Positron Emission Tomography With 3'-Deoxy-3'-[18F] Fluoro-thymidine ([18F]-FLT) for the Evaluation of Response to Neoadjuvant Chemotherapy for Cancers of the Breast
Study Start Date : November 2006
Actual Primary Completion Date : April 2012
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: TEP FLT Other: 3'-deoxy-3'-[18F]fluorothymidine

Primary Outcome Measures :
  1. Intensity of tumor uptake of 3'-deoxy-3'-(18F) fluorothymidine (18F-FLT) determined visually and correlated with histological or surgical response according to Sataloff criteria [ Time Frame: Post surgery ]

Secondary Outcome Measures :
  1. Intensity of tumor uptake of 18F-FLT by standardized uptake value (SUV) [ Time Frame: Post surgery ]
  2. Variation of tumoral uptake as seen by positron emission tomography (PET) before, during, and after therapy as determined visually and by SUV [ Time Frame: Post surgery ]
  3. Intensity of the tumoral uptake of 18F-FLT on initial exam visually and by SUV [ Time Frame: post surgery ]
  4. Histologic parameters: type, grade, mitotic index, CCIS , and microbiopsy embols after first course of chemotherapy (and on microbiopsy before therapeutic change of sequence in patients receiving bisequential chemotherapy) [ Time Frame: post surgery ]
  5. Immunohistochemical evaluation (estrogen and progesterone receptors, c-erbB2, Ki-67, e-cadherin) [ Time Frame: Post-surgery ]
  6. Rate of thymidine kinase 1 (TK1) [ Time Frame: Post surgery ]
  7. Toxicity by CTC-AE v. 3.0 [ Time Frame: Post surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


Inclusion criteria:

  • Histologically confirmed unilateral breast cancer

    • T2 or T3, any N, M0
    • Unifocal by mammography and ultrasound
  • Negative for c-erbB2 by immunohistochemistry (IHC)
  • Planning neoadjuvant chemotherapy comprising anthracyclines and/or taxanes, alone or combined
  • Measurable disease by ultrasound
  • Hormone receptor status not specified

Exclusion criteria:

  • Bilateral disease
  • Multifocal tumor
  • Invasive grade I lobular cancer
  • Metastatic disease
  • Stage ≥ T4 disease
  • Cutaneous invasion, major adherence, or inflammatory disease
  • Tumor overexpressing c-erbB2 by IHC (HER 2+++)
  • Suspected clinical or radiological lesion (examined or not)


Inclusion criteria:

  • ECOG performance status 0-1
  • Female
  • Menopausal status not specified
  • Hematologic, hepatic, and renal function normal
  • Not pregnant or nursing
  • Fertile patients must use effective contraception

Exclusion criteria:

  • Alcohol dependency or prior reaction to ethanol injection
  • Impossible to receive study therapy due to geographical, social, or psychological reasons
  • Prisoners or patients under supervision


Inclusion criteria:

  • See Disease Characteristics

Exclusion criteria:

  • Participation in another concurrent therapeutic study with an experimental drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00534274

Centre Hospitalier Regional et Universitaire d'Angers
Angers, France, 49033
Centre Paul Papin
Angers, France, 49036
Centre Hospitalier de la Cote Basque
Bayonne, France, 64100
Hopital Saint Andre
Bordeaux, France, 33075
CHU de Bordeaux - Hopital Pellegrin
Bordeaux, France, 33076
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France, 33300
CHU Hopital A. Morvan
Brest, France, 29609
Centre Regional Francois Baclesse
Caen, France, 14076
Centre Jean Perrin
Clermont-Ferrand, France, 63011
Centre de Lutte Contre le Cancer Georges-Francois Leclerc
Dijon, France, 21079
Centre Oscar Lambret
Lille, France, 59020
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
Marseille, France, 13273
CHU de la Timone
Marseille, France, 13385
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Centre Regional Rene Gauducheau
Nantes-Saint Herblain, France, 44805
CHR Hotel Dieu
Nantes, France, 44093
Centre Antoine Lacassagne
Nice, France, 06189
Hopital de l'Archet CHU de Nice
Nice, France, F-06202
Hopital Saint-Louis
Paris, France, 75475
Hopital Tenon
Paris, France, 75970
CHU Poitiers
Poitiers, France, 86021
Centre Henri Becquerel
Rouen, France, 76038
Centre Rene Huguenin
Saint Cloud, France, 92211
Centre Hospitalier Universitaire Bretonneau de Tours
Tours, France, 37044
Sponsors and Collaborators
Study Chair: Olivier Couturier, MD Centre Hospitalier Regional et Universitaire d'Angers

Responsible Party: UNICANCER Identifier: NCT00534274     History of Changes
Other Study ID Numbers: FLT01 - UC-0140/0505
2005-005166-37 ( EudraCT Number )
First Posted: September 24, 2007    Key Record Dates
Last Update Posted: December 16, 2014
Last Verified: December 2014

Keywords provided by UNICANCER:
stage II breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents